
AIM ImmunoTech AIM
€ 0.29
0.33%
Geschäftsbericht 2025
hinzugefügt 27.03.2026
AIM ImmunoTech Langfristiger Schuldenstrom 2011-2026 | AIM
Langfristiger Schuldenstrom Jährlich AIM ImmunoTech
| 2025 | 2024 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 250 K | 239 K | 178 K | 37 K | 47 K | 38 K | 199 K | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 250 K | 37 K | 141 K |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
103 K | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
7.93 M | $ 19.14 | 0.74 % | $ 895 M | ||
|
Anika Therapeutics
ANIK
|
1.6 M | $ 14.74 | -0.2 % | $ 216 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
Autolus Therapeutics plc
AUTL
|
4.56 M | $ 1.63 | 3.5 % | $ 434 M | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
BioNTech SE
BNTX
|
45 M | $ 94.9 | 0.82 % | $ 22.9 B | ||
|
Athira Pharma
ATHA
|
465 K | - | - | $ 269 M | ||
|
Esperion Therapeutics
ESPR
|
2.1 M | $ 3.13 | -0.48 % | $ 651 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
773 K | - | 0.74 % | $ 768 M | ||
|
Exelixis
EXEL
|
27.9 M | $ 49.35 | 2.47 % | $ 13.4 B | ||
|
Fortress Biotech
FBIO
|
2.13 M | $ 2.36 | -1.26 % | $ 65.8 M | ||
|
Forte Biosciences
FBRX
|
416 K | $ 24.9 | 3.65 % | $ 322 M | ||
|
AbbVie
ABBV
|
194 M | $ 203.32 | 0.97 % | $ 360 B | ||
|
Gilead Sciences
GILD
|
102 M | $ 133.2 | 1.42 % | $ 166 B | ||
|
Compugen Ltd.
CGEN
|
768 K | $ 2.82 | -2.76 % | $ 263 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
9.96 M | $ 22.41 | 0.04 % | $ 3.71 B | ||
|
Genmab A/S
GMAB
|
26 M | $ 26.36 | -0.26 % | $ 1.71 B | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 3.46 | -1.98 % | $ 5.7 M | ||
|
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M | ||
|
Grifols, S.A.
GRFS
|
117 M | $ 8.05 | -0.62 % | $ 5.47 B | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | ||
|
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | ||
|
Arcutis Biotherapeutics
ARQT
|
294 K | $ 21.09 | -0.4 % | $ 2.68 B | ||
|
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | ||
|
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | ||
|
Applied Therapeutics
APLT
|
429 K | - | - | $ 8.42 M |